2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
57
Breast Neoplasms
35
Neoplasms
32
Parkinson Disease 4, Autosomal Dominant Lewy Body
25
Multiple Myeloma
24
Leukemia, Myeloid, Acute
20
Recurrence
19
Colorectal Neoplasms
17
Neoplasm Metastasis
17
Lymphoma, Non-Hodgkin
15
Ovarian Neoplasms
15
Carcinoma, Renal Cell
14
Leukemia
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Melanoma
14
Lymphoma, Follicular
12
Lung Neoplasms
11
Myelodysplastic Syndromes
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Urinary Bladder Neoplasms
11
Carcinoma, Hepatocellular
10
Hematologic Neoplasms
10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Adenocarcinoma
9
Glioma
9
Lymphoma
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Mantle-Cell
9
Prostatic Neoplasms
9
Stomach Neoplasms
9
Interventions
olaparib
1
cc-486
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Pathologic Complete Response
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA